Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday, Zacks.com reports.
According to Zacks, “Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. “
Other analysts have also recently issued reports about the stock. Cowen restated a “buy” rating on shares of Trillium Therapeutics in a report on Thursday, August 15th. HC Wainwright cut shares of Trillium Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, August 19th.
Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last released its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.19. The firm had revenue of $0.03 million during the quarter. As a group, analysts forecast that Trillium Therapeutics will post -1.34 earnings per share for the current year.
An institutional investor recently bought a new position in Trillium Therapeutics stock. Marshall Wace LLP purchased a new stake in Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) during the first quarter, according to its most recent 13F filing with the SEC. The firm purchased 110,282 shares of the biotechnology company’s stock, valued at approximately $73,000. Marshall Wace LLP owned approximately 0.42% of Trillium Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 23.88% of the company’s stock.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
Featured Story: Does the Dogs of the Dow strategy work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.